started · updated
Efferon develops pediatric blood purification device for sepsis
Medical technology startup Efferon has developed the Efferon NEO, a blood purification device specifically designed to treat pediatric sepsis. The device aims to reduce organ failure rates and accelerate recovery in children by removing both endotoxins and cytokines from the bloodstream simultaneously.
Co-founder and CEO Dima Romashin describes the dual-action mechanism as addressing both the ‘flames’ (endotoxins) and the ‘smoke’ (cytokines) of the body’s inflammatory response. This distinction is critical for pediatric patients, who have significantly lower circulating blood volumes than adults and require specialized physiological engineering.
In April 2026, the Efferon NEO received the CE mark under the European Union’s Medical Device Regulation, making it Europe’s first multimodal extracorporeal blood purification device engineered for pediatric sepsis. The technology is currently used in intensive care units across 30 countries, including Thailand, Saudi Arabia, and various European nations. The company is now preparing to file for FDA approval and projects reaching $2 million in annualized revenue by the end of 2026.